Research ArticleOpen Access

Mpviropack Plus: Real Life Study

Volume 3 - Issue 3

Mohamed Baddar⁴, Taher el Zanaty², Reda Amer², Mohsen Salama⁵, Ramy M Elsharkawy⁶, Hazem Elbedawei⁷ , Alaa Osman Elroby⁸, Osama A Sabry⁹, Tamer G¹⁰ , Hares M¹¹ , Ayman El Badawy¹³, Nader A Nemr¹², Mohamed M Aamer¹⁴, Nashaat Hawass¹², George Marzouk¹⁵, Sherif Ragheb¹⁵, Mohamed B Hashem*¹ and Esmat G¹

Author Information Open or Close
- ¹Endemic medicine department, Cairo University, Egypt
- ²Internal medicine department, Cairo University, Egypt
- ³Internal medicine department, National Hepatology and Tropical Medicine Research Institute, Egypt
- ⁴Ain Shams University, Egypt
- ⁵Hepatology Institute, Menoufia, Egypt
- ⁶Gastroenterology department, Sohag University, Egypt
- ⁷Medical insurance center, Tanta, Egypt
- ⁸Gastroenterology and Hepatology department, El fayoum el aam hospital, Egypt
- ⁹Internal medicine department, Zagazig hospital, Egypt
- ¹⁰Ain Shams specialized hospital, Damietta, Egypt
- ¹¹Kafr Saad hospital, Damietta, Egypt
- ¹²Endemic and Infectious Diseases Faculty of Medicine Suez Canal University, Egypt
- ¹³Internal medicine department, Banha University, Egypt
- ¹⁴Shebin El- Kom teaching hospital, Egypt
- ¹⁵Marcyrl Ph Ind, Egypt
*Corresponding author: Mohamed B Hashem, Endemic medicine department, Cairo University, Giza, Egypt

Received: March 12, 2018; Published: April 05, 2018

DOI: 10.26717/BJSTR.2018.03.000918

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

Egypt has the highest prevalence of HCV worldwide. It is estimated to be 7.3% which is considered more than double the global prevalence that is estimated to be 3% according to the World Health Organization (WHO). The main genotype in Egypt is genotype 4 [1]. For many years ago, HCV treatment remained a challenge, where the available regimens were the moderately potent but poorly tolerated combination of pegylated interferon (PegIFN) and ribavirin for 24 or 48 weeks [2]. Using this combination, HCV genotype 4 patients had intermediate SVR rates (50-60%) [3]. Since 2011, multiple new drugs acting on specific enzymatic sites throughout the HCV life cycle were developed (direct acting antiviral drugs DAAs). DAAs are more potent than the INF/RBV with bettersafety profile. DAAs are now widely available worldwide [4].

Abbreviations: WHO: World Health Organization; PegIFN: Pegylated Interferon; DAAs: Direct Acting Antiviral Drugs Daas; AST: Aspartate Transaminase; ALT: Alanine Transaminase; ALB: Albumin; INR: International Normalized Ratio; CBC: Complete Blood Count; AFP: Alpha Feto Protein; FBS: Fasting Blood Sugar; SVR: Sustained Virological Response